References
- Dejea C, Wick E, Sears CL. Bacterial oncogenesis in the colon. Future Microbiol. 2013; 8:445–60.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424.
- Afinidad-Bernardo D. Colorectal cancer now Philippines’ number 1 cancer [Internet]. 2021 [cited 2021 Dec 21]. Available from: https://www.philstar.com/lifestyle/health-and-family/2017/03/08/1677440/colorectal-cancer-now-philippines-number-1-cancer. [Retrieved 2021 Dec 21].
- Purcell RV, Pearson J, Aitchison A, Dixon L, Frizelle FA, Keenan JI. Colonization with enterotoxigenic Bacteroides fragilis is associated with early-stage colorectal neoplasia. PLoS One. 2017; 12:e0171602. doi: 10.1371/journal.pone.0171602
- Sears CL. Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes. Clin Microbiol Rev. 2009; 22:349–69.
- Wu S, Lim KC, Saidi RF, Sears CL. Bacteroides fragilis enterotoxin cleaves the zonula adherens protein, E-cadherin. Proc Natl Acad Sci U S A. 1998; 95:14979–84.
- Wu S, Morin PJ, Maouyo D, Sears CL. Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology. 2003; 124:392–400.
- Rhee KJ, Wu S, Wu X, Huso DL, Karim B, Franco AA, et al. Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice. Infect Immun. 2009; 77:1708–18.
- Boleij A, Hechenbleikner EM, Goodwin AC, Badani R, Stein EM, Lazarev MG, et al. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis. 2015; 60:208–15.
- Viljoen KS, Dakshinamurthy A, Goldberg P, Blackburn JM. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between Fusobacterium spp., Enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. PLoS One. 2015; 10:e0119462. doi: 10.1371/journal.pone.0119462
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61:344–49.
- Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods. 1998; 221:35–41.
- Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009; 15:1016–22.
- Magat EM, Balanag GA, Cariño AM, Fellizar A, Ortin TS, Guevarra L Jr, Albano PM. Clostridioides difficile antibody response of colorectal cancer patients versus clinically healthy individuals. Biosci Microbiota Food Health. 2020; 39:123–7.
- Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012; 10:575–82.
- Lee KH, Shim KS, Lim IS, Chae SA, Yun SW, Lee NM, et al. Changes in hepatitis B virus antibody titers over time among children: a single center study from 2012 to 2015 in an urban of South Korea. BMC Pediatr. 2017; 17:164. doi: 10.1186/s12887-017-0924-7
- Bio-rad. Helpful ELISA hints [Internet]. 2021 [cited 2021 July 20]. Available from: https://www.bio-rad-antibodies.com/helpful-elisa-hints.html.
- Guevarra LA Jr, Afable ACF, Belza PJO, Dy KJS, Lee SJQ, Sy-Ortin TT, Albano PMSP. Immunogenicity of a Fap2 peptide mimotope of Fusobacterium nucleatum and its potential use in the diagnosis of colorectal cancer. Infect Agent Cancer. 2018; 13:11. doi: 10.1186/s13027-018-0184-7
- Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009; 22:191–7.